116 related articles for article (PubMed ID: 18562053)
1. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.
Liu J; Yu Q; Stone GW; Yue FY; Ngai N; Jones RB; Kornbluth RS; Ostrowski MA
Vaccine; 2008 Jul; 26(32):4062-72. PubMed ID: 18562053
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
Russell ND; Graham BS; Keefer MC; McElrath MJ; Self SG; Weinhold KJ; Montefiori DC; Ferrari G; Horton H; Tomaras GD; Gurunathan S; Baglyos L; Frey SE; Mulligan MJ; Harro CD; Buchbinder SP; Baden LR; Blattner WA; Koblin BA; Corey L;
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):203-12. PubMed ID: 17106277
[TBL] [Abstract][Full Text] [Related]
3. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination.
Tomalka JA; Pelletier AN; Fourati S; Latif MB; Sharma A; Furr K; Carlson K; Lifton M; Gonzalez A; Wilkinson P; Franchini G; Parks R; Letvin N; Yates N; Seaton K; Tomaras G; Tartaglia J; Robb ML; Michael NL; Koup R; Haynes B; Santra S; Sekaly RP
Nat Immunol; 2021 Oct; 22(10):1294-1305. PubMed ID: 34556879
[TBL] [Abstract][Full Text] [Related]
4. Investigation of Immunostimulatory Effects of IFN-γ Cytokine and CD40 Ligand Costimulatory Molecule for Development of HIV-1 Therapeutic Vaccine Candidate.
Heidarnejad F; Bolhassani A; Ajdary S; Milani A; Sadeghi SA
Adv Biol (Weinh); 2024 Feb; 8(2):e2300402. PubMed ID: 37840398
[TBL] [Abstract][Full Text] [Related]
5. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors.
Wongthida P; Schuelke MR; Driscoll CB; Kottke T; Thompson JM; Tonne J; Stone C; Huff AL; Wetmore C; Davies JA; Parker AL; Evgin L; Vile RG
Neuro Oncol; 2020 Dec; 22(12):1757-1770. PubMed ID: 32459315
[TBL] [Abstract][Full Text] [Related]
6. The immunogenicity of p24 protein from HIV-1 virus is strongly supported and modulated by coupling with liposomes and mannan.
Zachová K; Bartheldyová E; Hubatka F; Křupka M; Odehnalová N; Turánek Knötigová P; Vaškovicová N; Sloupenská K; Hromádka R; Paulovičová E; Effenberg R; Ledvina M; Raška M; Turánek J
Carbohydr Polym; 2024 May; 332():121844. PubMed ID: 38431385
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.
Smith KA; Andjelic S; Popmihajlov Z; Kelly-Rossini L; Sass A; Lesser M; Benkert S; Waters C; Ruitenberg J; Bellman P
PLoS Clin Trials; 2007 Jan; 2(1):e5. PubMed ID: 17260026
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40⁻CD154 Costimulatory Protein-Protein Interaction.
Bojadzic D; Chen J; Alcazar O; Buchwald P
Molecules; 2018 May; 23(5):. PubMed ID: 29751636
[TBL] [Abstract][Full Text] [Related]
9. In silico designing of novel epitope-based peptide vaccines against HIV-1.
Heidarnejad F; Namvar A; Sadat SM; Pordanjani PM; Rezaei F; Namdari H; Arjmand S; Bolhassani A
Biotechnol Lett; 2024 Jun; 46(3):315-354. PubMed ID: 38403788
[TBL] [Abstract][Full Text] [Related]
10. CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8
Choi H; Lee HJ; Sohn HJ; Kim TG
BMC Immunol; 2023 Jun; 24(1):15. PubMed ID: 37391734
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
Silva de Castro I; Gordon SN; Liu J; Bissa M; McKinnon K; Trinh HV; Doster MN; Schifanella L; Liyanage NP; Cao J; Cheng O; Foulds K; Roederer M; Koup RA; Shen X; Tomaras GD; Venzon DJ; Forthal DN; Fouts T; Montefiori DC; Tartaglia J; Rao M; Ostrowski M; Franchini G; Vaccari M
J Virol; 2020 Feb; 94(6):. PubMed ID: 31896599
[TBL] [Abstract][Full Text] [Related]
12. Role of HTLV-1 orf-I encoded proteins in viral transmission and persistence.
Sarkis S; Galli V; Moles R; Yurick D; Khoury G; Purcell DFJ; Franchini G; Pise-Masison CA
Retrovirology; 2019 Dec; 16(1):43. PubMed ID: 31852543
[TBL] [Abstract][Full Text] [Related]
13. Development of targeted adjuvants for HIV-1 vaccines.
Liu J; Ostrowski M
AIDS Res Ther; 2017 Sep; 14(1):43. PubMed ID: 28893282
[TBL] [Abstract][Full Text] [Related]
14. HIV DNA Vaccine: Stepwise Improvements Make a Difference.
Felber BK; Valentin A; Rosati M; Bergamaschi C; Pavlakis GN
Vaccines (Basel); 2014 May; 2(2):354-79. PubMed ID: 26344623
[TBL] [Abstract][Full Text] [Related]
15. DNA/MVA Vaccines for HIV/AIDS.
Iyer SS; Amara RR
Vaccines (Basel); 2014 Feb; 2(1):160-78. PubMed ID: 26344473
[TBL] [Abstract][Full Text] [Related]
16. The evolution of poxvirus vaccines.
Sánchez-Sampedro L; Perdiguero B; Mejías-Pérez E; García-Arriaza J; Di Pilato M; Esteban M
Viruses; 2015 Apr; 7(4):1726-803. PubMed ID: 25853483
[TBL] [Abstract][Full Text] [Related]
17. Enhancing poxvirus vectors vaccine immunogenicity.
García-Arriaza J; Esteban M
Hum Vaccin Immunother; 2014; 10(8):2235-44. PubMed ID: 25424927
[TBL] [Abstract][Full Text] [Related]
18. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes.
Fan X; Hashem AM; Chen Z; Li C; Doyle T; Zhang Y; Yi Y; Farnsworth A; Xu K; Li Z; He R; Li X; Wang J
Mucosal Immunol; 2015 Jan; 8(1):211-20. PubMed ID: 25052763
[TBL] [Abstract][Full Text] [Related]
19. Modulation of HIV-1 immunity by adjuvants.
Moody MA
Curr Opin HIV AIDS; 2014 May; 9(3):242-9. PubMed ID: 24670321
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.
Kanagavelu S; Termini JM; Gupta S; Raffa FN; Fuller KA; Rivas Y; Philip S; Kornbluth RS; Stone GW
PLoS One; 2014; 9(2):e90100. PubMed ID: 24587225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
